Antidepressant drugs for neuropathic pain - an overview of Cochrane reviews (Q24186993)

3

0 references

Robert Andrew Moore

1

R Andrew Moore

0 references

Nanna B. Finnerup

Nanna B Finnerup

6

0 references

Michael P T Lunn

8

Michael PT Lunn

0 references

Eija Kalso

2

Eija A Kalso

0 references

Thomas Rudolf Tölle

5

Thomas Rudolf Tölle

0 references

author name string

Nadine Attal

Cochrane Database of Systematic Reviews

7

0 references

publication date

2 April 2015

0 references

published in

0 references

cites work

Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Prevalence of chronic pain with neuropathic characteristics in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Topical capsaicin (low concentration) for chronic neuropathic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Topical capsaicin (high concentration) for chronic neuropathic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Topical lidocaine for neuropathic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Efficacy of antidepressants as analgesics: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Indirect comparisons of competing interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Drugs for neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Epidemiology and Clinical Features of Idiopathic Trigeminal Neuralgia and Glossopharyngeal Neuralgia: Similarities and Differences, Rochester, Minnesota, 1945-1984

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Incidence of facial pain in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

A systematic review of antidepressants in neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Brain imaging of neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Pregabalin for acute and chronic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Amitriptyline for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Expect analgesic failure; pursue analgesic success

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Duloxetine use in chronic painful conditions--individual patient data responder analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Treatment of neuropathic pain: an overview of recent guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Antidepressants for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Antidepressants in the treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Neuropathic features of joint pain: a community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Publication bias in meta-analysis: its causes and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Can neuroimaging studies identify pain endophenotypes in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Neuropathic pain: redefinition and a grading system for clinical and research purposes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Neuropathic pain in the general population: a systematic review of epidemiological studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Deconstructing the neuropathic pain phenotype to reveal neural mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Amitriptyline versus placebo in postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Neuropathic pain: aetiology, symptoms, mechanisms, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

Antiepileptic drugs for neuropathic pain and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

7 January 2021

Anti-convulsants and anti-depressants.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

7 January 2021

A new definition of neuropathic pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

7 January 2021

Chronic pain: genes, plasticity, and phenotypes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011606

7 January 2021

10.1002/14651858.CD011606

Identifiers

DOI

0 references

Fatcat ID

release_ubn37rbqhfdutipp4rp7bvwk34

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ubn37rbqhfdutipp4rp7bvwk34

24 November 2022